Pepinemab + Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease
Conditions
Alzheimer Disease
Trial Timeline
Jul 22, 2021 → Jun 5, 2024
NCT ID
NCT04381468About Pepinemab + Placebo
Pepinemab + Placebo is a phase 1/2 stage product being developed by Vaccinex for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04381468. Target conditions include Alzheimer Disease.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04381468 | Phase 1/2 | Completed |
Competing Products
20 competing products in Alzheimer Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 44 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 77 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 + Placebo | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| donanemab | Eli Lilly | Phase 2 | 52 |
| ATH-1017 | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 25 |
| simufilam | Cassava Sciences | Phase 2 | 44 |
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 25 |